Price forecast of neratinib/neratinib in 2025

Neratinib/Neratinib (Neratinib) is an irreversible pan-HER receptor tyrosine kinase inhibitor (pan-HER TKI) that can simultaneously inhibit the HER1, HER2 and HER4 receptor signaling pathways. It is currently one of the representative innovative drugs in the adjuvant treatment of patients with HER2-positive breast cancer. Its greatest benefit is that it can effectively reduce the risk of postoperative recurrence of breast cancer and prolong disease-free survival (DFS), especially for patients with hormone receptor-positive (HR+) and HER2-positive patients. Neratinib prevents residual activation of tumor cells by long-term and sustained inhibition of HER family signaling, providing a new idea of u200bu200b"continuous blockade" treatment, allowing HER2-positive breast cancer to gradually develop towards chronic disease management.

From an economic perspective, as an original innovative drug, the price of neratinib has always been high. Domestic original drugs have been included in the Class B medical insurance catalog, but they are only reimbursable for specific indications (such as adjuvant treatment for HER2-positive early breast cancer after surgery and patients who have completed trastuzumab treatment). Taking 40mg*180 tablets as an example, the price before medical insurance is about RMB 7,000. In some areas, the patient pays out-of-pocket ratio after reimbursement is about 30%-50%. This price is still at a mid-range level compared to similar HER2-targeted drugs.

In overseas markets, the price of neratinib is more expensive, and the original research version in the United States sells for about more than US$10,000, reflecting its high-end positioning in the global market. However, with the emergence of generic drugs, the price gap has gradually narrowed. At present, pharmaceutical companies such as Lucius in Laos have launched a generic version with the same specifications of 40mg*180 tablets and a price of about 2,000 yuan. The pharmacodynamic ingredients are consistent with the original drug, providing patients with a more cost-effective choice. If a generic version is introduced domestically or a cross-border procurement mechanism is implemented in the future, it is expected that the price of neratinib will still have room to decline.

Reference materials:https://en.wikipedia.org/wiki/Neratinib